$8.17
4.22% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
NL0015285941
Symbol
IMTX
Sector
Industry

Immatics N.V Stock price

$8.17
-1.32 13.91% 1M
-2.91 26.26% 6M
-2.36 22.41% YTD
-0.76 8.51% 1Y
-3.76 31.52% 3Y
-6.88 45.71% 5Y
-6.88 45.71% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.36 4.22%
ISIN
NL0015285941
Symbol
IMTX
Sector
Industry

Key metrics

Market capitalization $975.14m
Enterprise Value $444.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.80
P/S ratio (TTM) P/S ratio 12.73
P/B ratio (TTM) P/B ratio 2.03
Revenue (TTM) Revenue $76.61m
EBIT (operating result TTM) EBIT $-109.46m
Free Cash Flow (TTM) Free Cash Flow $-47.75m
Cash position $569.21m
EPS (TTM) EPS $-0.90
P/E forward negative
P/S forward 12.69
EV/Sales forward 6.08
Short interest 6.84%
Show more

Is Immatics N.V a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Immatics N.V Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Immatics N.V forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Immatics N.V forecast:

Buy
100%

Financial data from Immatics N.V

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
77 77
52% 52%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
101% 101%
31%
- Research and Development Expense 142 142
33% 33%
185%
-99 -99
577% 577%
-129%
- Depreciation and Amortization 10 10
45% 45%
14%
EBIT (Operating Income) EBIT -109 -109
909% 909%
-143%
Net Profit -80 -80
366% 366%
-104%

In millions USD.

Don't miss a Thing! We will send you all news about Immatics N.V directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immatics N.V Stock News

Neutral
GlobeNewsWire
7 days ago
Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers
Positive
Seeking Alpha
about one month ago
Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation estimates suggest a potential stock price of ~$19.26 based on conservative revenue assumptions.
Neutral
GlobeNewsWire
about one month ago
H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The g...
More Immatics N.V News

Company Profile

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.

Head office Netherlands
CEO Harpreet Singh-Jasuja
Employees 343
Founded 2020
Website www.immatics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today